(Q38059459)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

title

Systemic sclerosis--challenges for clinical practice (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

author name string

Zsuzsanna H McMahan

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

language of work or name

English

0 references

publication date

13 November 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Rheumatology

17 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

volume

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

17 February 2020

page(s)

90-100

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23147899%20AND%20SRC:MED&resulttype=core&format=json

https://scigraph.springernature.com/pub.10.1038/nrrheum.2012.191

17 February 2020

exact match

0 references

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Low prevalence of anti-RNA polymerase III antibodies in a French scleroderma population: anti-RNA polymerase III scleroderma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

21 January 2018

Scleroderma renal crisis

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Clinical course of lung physiology in patients with scleroderma and interstitial lung disease: analysis of the Scleroderma Lung Study Placebo Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Clinical subsets, skin thickness progression rate, and serum antibody levels in systemic sclerosis patients with anti-topoisomerase I antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Patterns and predictors of change in outcome measures in clinical trials in scleroderma: an individual patient meta-analysis of 629 subjects with diffuse cutaneous systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Cyclophosphamide versus placebo in scleroderma lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A prospective open-label study of mycophenolate mofetil for the treatment of diffuse systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Long-term experience of mycophenolate mofetil for treatment of diffuse cutaneous systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A one-year, phase I/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Tyrosine kinase inhibitors in the treatment of systemic sclerosis: from animal models to clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Evaluation of the efficacy and safety of terguride in patients with fibromyalgia syndrome: results of a twelve-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Imatinib in active diffuse cutaneous systemic sclerosis: Results of a six-month, randomized, double-blind, placebo-controlled, proof-of-concept pilot study at a single center.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Autologous Stem cell Transplantation International Scleroderma (ASTIS) trial: hope on the horizon for patients with severe systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Successes and failures of stem cell transplantation in autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

21 January 2018

Scleroderma Lung Disease

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Long term effects of cyclophosphamide treatment on lung function and survival in scleroderma patients with interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Isolated pulmonary hypertension in scleroderma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Telangiectases in scleroderma: a potential clinical marker of pulmonary arterial hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Late-age onset systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Early detection of pulmonary arterial hypertension in systemic sclerosis: A French nationwide prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Disproportionate elevation of N-terminal pro-brain natriuretic peptide in scleroderma-related pulmonary hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Exercise-induced pulmonary hypertension associated with systemic sclerosis: four distinct entities.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of systemic sclerosis complications: what to use when first-line treatment fails--a consensus of systemic sclerosis experts

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Screening for pulmonary arterial hypertension in patients with systemic sclerosis: Clinical characteristics at diagnosis and long-term survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

European League Against Rheumatism (EULAR) Scleroderma Trial and Research group (EUSTAR) recommendations for the treatment of systemic sclerosis: methods of elaboration and results of systematic literature research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Systemic sclerosis and bilateral lung transplantation: a single centre experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Antireflux surgery preserves lung function in patients with gastroesophageal reflux disease and end-stage lung disease before and after lung transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Lung transplantation, gastroesophageal reflux, and fundoplication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

J. Maxwell Chamberlain Memorial Paper. Early fundoplication prevents chronic allograft dysfunction in patients with gastroesophageal reflux disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Antireflux surgery in the setting of lung transplantation: strategies for treating gastroesophageal reflux disease in a high-risk population

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Pulmonary arterial hypertension complicating connective tissue diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Demographic, clinical and antibody characteristics of patients with digital ulcers in systemic sclerosis: data from the DUO Registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Raynaud's phenomenon and digital ischemia: a practical approach to risk stratification, diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Arteriographic evaluation of vascular changes of the extremities in patients with systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Efficacy of tadalafil in secondary Raynaud's phenomenon resistant to vasodilator therapy: a double-blind randomized cross-over trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Contemporary management of Raynaud's phenomenon and digital ischaemic complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Intravenous iloprost infusion in patients with Raynaud phenomenon secondary to systemic sclerosis. A multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Oral iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis: a multicenter, placebo-controlled, double-blind study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Periarterial sympathectomy in scleroderma patients: intermediate-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Systematic review: pathophysiology and management of gastrointestinal dysmotility in systemic sclerosis (scleroderma).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Review article: clinical implications of enteric and central D2 receptor blockade by antidopaminergic gastrointestinal prokinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Domperidone: review of pharmacology and clinical applications in gastroenterology

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A systematic review of the efficacy of domperidone for the treatment of diabetic gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Domperidone treatment for gastroparesis: demographic and pharmacogenetic characterization of clinical efficacy and side-effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Current concepts in diabetic gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Erythromycin in the short- and long-term control of dyspepsia symptoms in patients with gastroparesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Gastrointestinal transit in patients with systemic sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Small intestinal bacterial overgrowth in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Small intestinal bacterial overgrowth in patients suffering from scleroderma: clinical effectiveness of its eradication.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Small intestinal bacterial overgrowth syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Use and abuse of hydrogen breath tests

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Malnutrition in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Home parenteral nutrition in patients with systemic sclerosis: a retrospective review of 12 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Malnutrition is common in systemic sclerosis: results from the Canadian scleroderma research group database

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Home parenteral nutrition--an effective and safe long-term therapy for systemic sclerosis-related intestinal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Calcinosis in rheumatic diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of cutaneous calciphylaxis with sodium thiosulfate: two case reports and a review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of calcinosis with diltiazem

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of cutaneous calcinosis in limited systemic sclerosis with minocycline

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Complete resolution of universal calcinosis in a patient with juvenile dermatomyositis using pamidronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Calcinosis cutis associated with amyopathic dermatomyositis: response to intravenous immunoglobulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of systemic sclerosis-associated calcinosis: a case report of rituximab-induced regression of CREST-related calcinosis and review of the literature.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A pilot study of acetic acid iontophoresis and ultrasound in the treatment of systemic sclerosis-related calcinosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A longitudinal study of anti-RNA polymerase III antibody levels in systemic sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

The many faces of scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Effect of mycophenolate sodium in scleroderma-related interstitial lung disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Comparison of methotrexate with placebo in the treatment of systemic sclerosis: a 24 week randomized double-blind trial, followed by a 24 week observational trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A randomized, controlled trial of methotrexate versus placebo in early diffuse scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Shifting our thinking about uncommon disease trials: the case of methotrexate in scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Stem cells: HSCT for systemic sclerosis--swallows and summers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Interstitial lung disease in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Is pulmonary arterial hypertension really a late complication of systemic sclerosis?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

High N-terminal pro-brain natriuretic peptide levels and low diffusing capacity for carbon monoxide as independent predictors of the occurrence of precapillary pulmonary arterial hypertension in patients with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Echocardiography and pulmonary function as screening tests for pulmonary arterial hypertension in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Significance of serum uric acid in pulmonary hypertension due to systemic sclerosis: a pilot study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Lung transplantation in scleroderma compared with idiopathic pulmonary fibrosis and idiopathic pulmonary arterial hypertension

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Lung transplantation in patients with scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Improved lung allograft function after fundoplication in patients with gastroesophageal reflux disease undergoing lung transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Transition from IV to subcutaneous prostacyclin: premature withdrawal?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Iloprost and cisaprost for Raynaud's phenomenon in progressive systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Oesophageal dilatation on high-resolution computed tomography scan of the lungs as a sign of scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Gastrointestinal motility disorders in scleroderma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Management of intestinal involvement in systemic sclerosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Diabetic gastroparesis: treatment with domperidone--a double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Octreotide treatment of chronic intestinal pseudoobstruction secondary to connective tissue diseases

31 March 2020

2 references

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

31 March 2020

12 December 2020

Is serum albumin a marker of malnutrition in chronic disease? The scleroderma paradigm

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

A case of calcinosis universalis successfully treated with low-dose warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Successful use of diltiazem in calcinosis caused by connective tissue disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Cutaneous calcinosis of scleroderma. Successful treatment with intralesional adrenal steroids

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Calcinosis cutis in juvenile dermatomyositis responsive to aluminum hydroxide treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of calcinosis cutis by extracorporeal shock-wave lithotripsy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Treatment of traumatic myositis ossificans with acetic acid iontophoresis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRRHEUM.2012.191

Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole

31 March 2020

1 reference

12 December 2020

Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers

1 reference

12 December 2020

Rapid improvement of calcinosis in juvenile dermatomyositis with alendronate therapy.

1 reference

12 December 2020

Pulmonary arterial hypertension and severe pulmonary fibrosis in systemic sclerosis patients with a nucleolar antibody.

1 reference

12 December 2020

High resolution computed tomography in fibrosing alveolitis associated with systemic sclerosis.

1 reference

12 December 2020

Natural history of mild-moderate pulmonary hypertension and the risk factors for severe pulmonary hypertension in scleroderma.

1 reference

12 December 2020

Efficacy of probenecid for a patient with juvenile dermatomyositis complicated with calcinosis

1 reference

12 December 2020

Preventive effect of an oral prostacyclin analog, beraprost sodium, on digital necrosis in systemic sclerosis. French Microcirculation Society Multicenter Group for the Study of Vascular Acrosyndromes

1 reference

12 December 2020

Regression of cutis calcinosis with diltiazem in adult dermatomyositis

1 reference

12 December 2020

Metoclopramide response in patients with early diffuse systemic sclerosis. Effects on esophageal motility abnormalities.

1 reference

12 December 2020

Calcinosis universalis complicating juvenile dermatomyositis: resolution during probenecid therapy

1 reference

12 December 2020

A novel treatment for ulcerative calcinosis cutis

1 reference

12 December 2020

Severe restrictive lung disease in systemic sclerosis.

1 reference

12 December 2020

Ulnar artery involvement in systemic sclerosis (scleroderma).

1 reference

12 December 2020

Criteria for the classification of early systemic sclerosis.

1 reference

12 December 2020

Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study

1 reference

12 December 2020

The diagnosis of small bowel bacterial overgrowth. Reliability of jejunal culture and inadequacy of breath hydrogen testing

1 reference

12 December 2020